Study guide
16.5 Genetics and Health: Inheritance, Screening & Counseling
Combined Medical Services Examination UPSC CMS
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Exam Structure, Logistics & Pattern
1.1 UPSC CMS Examination Overview & Eligibility 1.2 Two-Paper Written Exam Pattern & Negative Marking 1.3 Personality Test, Service Allocation & Career Paths
2 Chapter 2: General Medicine - Cardiology & Respiratory
2.1 Coronary Artery Disease & Acute Myocardial Infarction 2.2 Heart Failure & Cardiac Arrhythmias 2.3 Community-Acquired Pneumonia & Pulmonary Tuberculosis 2.4 COPD, Bronchial Asthma & Pulmonary Embolism
3 Chapter 3: General Medicine - Gastroenterology & Hepatology
3.1 Peptic Ulcer Disease & Upper GI Bleeding 3.2 Liver Cirrhosis & Portal Hypertension 3.3 Acute & Chronic Viral Hepatitis & Pancreatitis 3.4 Inflammatory Bowel Disease & Malabsorption Syndromes
4 Chapter 4: General Medicine - Nephrology & Endocrinology
4.1 Acute Kidney Injury & Chronic Kidney Disease 4.2 Glomerulonephritis, Nephrotic Syndrome & Electrolyte Imbalances 4.3 Diabetes Mellitus: Diagnosis, Complications & Management 4.4 Thyroid Disorders & Adrenal Gland Dysfunction
5 Chapter 5: General Medicine - Neurology, Haematology & Infection
5.1 Cerebrovascular Accidents (Stroke) & Epilepsy 5.2 Approach to Anaemia: Microcytic, Megaloblastic & Haemolytic 5.3 Acute & Chronic Leukaemias and Lymphomas 5.4 Tropical & Endemic Infections: Malaria, Typhoid & Dengue
6 Chapter 6: General Medicine - Emergency Medicine & Toxicology
6.1 Acute Anaphylaxis, Sepsis & Cardiopulmonary Resuscitation 6.2 Organophosphate, Paracetamol & Snakebite Toxicology 6.3 Common Dermatological & Psychiatric Manifestations in Internal Medicine 6.4 Musculoskeletal System & Adult Rheumatology
7 Chapter 7: Paediatrics - Neonatology & Child Growth
7.1 Newborn Care, Neonatal Resuscitation & APGAR Score 7.2 Prematurity, Low Birth Weight & Neonatal Jaundice 7.3 Infant & Child Growth & Developmental Milestones
8 Chapter 8: Paediatrics - Child Health & Nutrition
8.1 Protein-Energy Malnutrition (PEM) & Micronutrient Deficiencies 8.2 Universal Immunization Programme (UIP) & Child Vaccines 8.3 Pediatric Diarrhoea, Dehydration & Respiratory Emergencies 8.4 Birth Defects, Genetic Counseling, Autism & Paediatric Accidents/Poisoning
9 Chapter 9: Surgery - General Surgery, Wounds & Shock
9.1 Wound Healing, Surgical Site Infections & Gas Gangrene 9.2 Pathophysiology of Shock & Perioperative Fluid Therapy 9.3 Acute Abdomen: Appendicitis, Peritonitis & Intestinal Obstruction 9.4 Classification, Resuscitation & Management of Thermal Burns 9.5 Medicolegal & Ethical Issues in Surgery
10 Chapter 10: Surgery - Surgical Specialties I
10.1 Inguinal, Femoral & Ventral Hernias 10.2 Benign Breast Diseases & Breast Carcinoma 10.3 Solitary Thyroid Nodule & Thyroid Carcinoma 10.4 Benign Prostatic Hyperplasia & Renal Calculi
11 Chapter 11: Surgery - ENT, Orthopaedics & Anaesthesia
11.1 Acute Otitis Media, Tonsillitis & Epistaxis 11.2 Cataract, Glaucoma & Red Eye Emergencies 11.3 Principles of Fracture Management & Common Dislocation 11.4 Principles of Local, Regional & General Anaesthesia 11.5 Neurosurgery: Raised ICP, Head Injury & CNS Lesions 11.6 Thoracic Surgery: Chest Trauma, Pleural & Lung Disease
12 Chapter 12: Obstetrics - Antenatal Care & Complications
12.1 Antenatal Care, Maternal Nutrition & Fetal Assessment 12.2 Preeclampsia, Eclampsia & Gestational Hypertension 12.3 Antepartum Haemorrhage: Placenta Previa & Abruptio Placentae 12.4 Anemia in Pregnancy & Gestational Diabetes Mellitus 12.5 Spontaneous & Recurrent Abortion: Recognition & Management
13 Chapter 13: Obstetrics & Gynaecology - Labor & PPH
13.1 Normal Labor Mechanisms & Partograph Monitoring 13.2 Malpresentations, Breech & Obstructed Labor 13.3 Postpartum Haemorrhage (PPH) Causes & Management 13.4 Puerperal Sepsis & Postnatal Maternal Care
14 Chapter 14: Gynaecology & Family Planning
14.1 Abnormal Uterine Bleeding & Uterine Fibroids 14.2 Cervical Screening (Pap Smear) & Pelvic Inflammatory Disease 14.3 Temporary & Permanent Contraceptive Methods in India 14.4 Medical Termination of Pregnancy (MTP): Law & Methods
15 Chapter 15: PSM - Epidemiology & Biostatistics
15.1 Principles of Epidemiology & Disease Transmission 15.2 Observational & Experimental Epidemiological Study Designs 15.3 Evaluation of Screening Tests: Sensitivity, Specificity & Predictive Value 15.4 Biostatistics: Sampling, Central Tendency & Significance Testing
16 Chapter 16: PSM - Disease Epidemiology & Programmes
16.1 Epidemiology & Control of TB, Malaria & Dengue 16.2 National Tuberculosis Elimination Programme & NVBDCP 16.3 Epidemiology of Hypertension, Diabetes & Cancer in India 16.4 Cold Chain Management & Vaccine Logistics in India 16.5 Genetics and Health: Inheritance, Screening & Counseling
17 Chapter 17: PSM - Health Planning & Environmental Health
17.1 Demography, Fertility Rates & Family Welfare Indicators 17.2 Safe Water Supply, Waste Disposal & Air Pollution 17.3 Occupational Health Hazards & Pneumoconioses 17.4 Health Care Delivery System, Ayushman Bharat & National Health Mission 17.5 International Health: WHO, Global Agencies & SDG 3 17.6 Medical Sociology & Health Education
16.5 Genetics and Health: Inheritance, Screening & Counseling
Key Takeaways Explain This Topic AI
Human inheritance follows Mendelian patterns — autosomal dominant (each child of an affected parent has a 50% risk; e.g. Huntington disease), autosomal recessive (25% recurrence risk; e.g. thalassaemia, sickle cell, CF) and X-linked recessive (carrier mothers, affected sons; e.g. haemophilia, Duchenne muscular dystrophy).
India carries a high burden of haemoglobinopathies — β-thalassaemia carrier frequency ~3–17% by region and sickle cell disease concentrated in central/tribal belts; carrier screening and prenatal diagnosis form the public-health prevention strategy.
Population genetic screening tiers are carrier screening (pre-conception/at-risk couples), prenatal diagnosis (CVS 10–13 weeks, amniocentesis 15–20 weeks) and newborn screening (congenital hypothyroidism, G6PD, sickle cell where prevalent).
Periconceptional folic acid supplementation (400 µg/day, ≥4 weeks pre-conception) reduces neural tube defect recurrence and first occurrence — the single most cost-effective genetic primary-prevention intervention.
Non-directive genetic counseling presents recurrence risks and reproductive options without coercion; consanguinity increases autosomal recessive disease burden and warrants carrier screening.
Last updated: July 2026
16.5 Genetics and Health: Inheritance, Screening & Counseling
High-Yield Core Concept: The PSM syllabus lists Genetics and Health as a distinct topic. CMS questions test the recurrence-risk percentages for Mendelian disorders, the Indian public-health burden of haemoglobinopathies, and the screening tests available at each stage of the reproductive lifecycle.
1. Modes of Inheritance
Pattern Recurrence risk Hallmarks Examples
Autosomal dominant 50% Vertical transmission, both sexes affected, variable penetrance Huntington disease, familial hypercholesterolaemia, achondroplasia, Marfan
Autosomal recessive 25% Horizontal (sibs), often no family history, consanguinity ↑ risk β-thalassaemia, sickle cell, cystic fibrosis, phenylketonuria
X-linked recessive 50% of sons of a carrier mother Affected males, carrier females; no male-to-male transmission Haemophilia A/B, Duchenne muscular dystrophy, red-green colour blindness
X-linked dominant 50% Both sexes affected, often lethal in males Hypophosphatamic rickets
Mitochondrial All children of affected mother Maternal transmission only Leber hereditary optic neuropathy, MELAS
Multifactorial Empirical (~3–5%) Threshold + environment NTD, diabetes, hypertension, cleft lip/palate
Chromosomal disorders: Down syndrome (trisomy 21, 1:700, ↑ maternal age), Edwards (18), Patau (13), Turner (45,X), Klinefelter (47,XXY).
2. Burden of Genetic Disease in India
Haemoglobinopathies dominate the Indian genetic burden:
β-thalassaemia — carrier frequency 3–17% (mean ~3–4%), higher in Sindhi, Punjabi, Gujarati, Bengali communities; ~10,000 thalassaemia major births/year.
Sickle cell disease — concentrated in central, eastern and tribal belts (Odisha, Chhattisgarh, Madhya Pradesh, Maharashtra, Gujarat); the S allele reaches carrier frequency >20% in some tribal groups.
Haemophilia — estimated 1:10,000 males (A) and 1:50,000 (B).
Consanguinity , common in south Indian and some Muslim communities, increases autosomal recessive disease risk.
3. Population Genetic Screening
Three-tier screening aligns with the reproductive lifecycle:
Tier When Test Purpose
Carrier screening Pre-conception / antenatal Hb electrophoresis/HPLC for at-risk couples; mutation panel Identify carriers to offer prenatal diagnosis
Prenatal diagnosis 10–20 weeks CVS 10–13 wks , amniocentesis 15–20 wks , NIPT/cffDNA Diagnose affected fetus; reproductive choice
Newborn screening Birth / 48–72 h Heel-prick (TSH/T4 for CH, G6PD, sickle cell where prevalent) Early treatment of treatable inherited disease
Prenatal diagnostic techniques are governed by the PCPNDT Act 1994 — usable only for detecting genetic/metabolic/chromosomal disorders, never sex determination.
4. Genetic Counseling
A communication process conveying recurrence risk and reproductive options. Core principles:
Non-directive — present risks and options, respect autonomy.
Pre-conception ideally — most choices exist before pregnancy.
Recurrence-risk figures: AR 25%, AD 50%, X-linked recessive 50% of carrier mother's sons, multifactorial empirical ~3–5%.
Address psychosocial, ethical and cultural dimensions; offer support groups.
Indications: advanced maternal age (≥35), previous affected child, family history of genetic disease, parental consanguinity, abnormal prenatal screening/ultrasound, recurrent pregnancy loss.
5. Primary & Secondary Prevention
Primary prevention (before disease occurs):
Periconceptional folic acid — 400 µg/day starting ≥4 weeks before conception through first trimester reduces neural tube defect risk by up to 70%; 4 mg/day for women with a prior NTD-affected pregnancy.
Avoid teratogens (alcohol, certain drugs, radiation), rubella vaccination pre-conception, optimise diabetes control.
Secondary prevention (early detection):
Prenatal screening — first-trimester combined screen (NT + PAPP-A + free β-hCG), quadruple test, anomaly scan at 18–20 weeks.
Newborn screening for congenital hypothyroidism, G6PD deficiency, sickle cell disease (in high-prevalence states).
Thalassaemia prevention programme (national model): awareness → carrier screening → prenatal diagnosis → option of termination of affected fetus — implemented through regional thalassaemia centres.
6. Common Chromosomal & Multifactorial Disorders in Practice
CMS genetics questions favour a handful of high-yield chromosomal and multifactorial conditions:
Disorder Karyotype / basis Key features
Down syndrome Trisomy 21 (95%), translocation (4%), mosaic (1%) Flat face, epicanthal folds, single palmar crease, AV canal, duodenal atresia, hypothyroidism, ↑ maternal age risk
- Edwards syndrome Trisomy 18 Clenched fists, rocker-bottom feet, low birth weight, short life expectancy
- Patau syndrome Trisomy 13 Cleft lip/palate, polydactyly, holoprosencephaly
- Turner syndrome 45,X Short stature, webbed neck, streak ovaries, coarctation of aorta, primary amenorrhoea
- Klinefelter syndrome 47,XXY Tall, gynaecomastia, small firm testes, infertility, learning difficulties
Prenatal screening integrates first-trimester combined test (NT + PAPP-A + free β-hCG, performed 11–13+6 weeks), the quadruple test (15–22 weeks: αFP, hCG, uE3, inhibin-A), and the anomaly scan at 18–20 weeks. A raised αFP flags open neural tube defects and abdominal wall defects; a low αFP with high hCG raises Down syndrome risk. Diagnostic confirmation is by CVS or amniocentesis with karyotype/microarray, governed by the PCPNDT Act.
Multifactorial inheritance applies to common conditions with a polygenic-plus-environment basis — neural tube defects, cleft lip/palate, congenital heart disease, diabetes and hypertension. Recurrence risk is empirical (~3–5%) and counselling combines family-history assessment with primary prevention (e.g. periconceptional folic acid for NTD).
Key Takeaways for the CMS Candidate
Recurrence risk by inheritance pattern: AD 50%, AR 25%, X-linked recessive 50% of sons of a carrier — the most testable numbers.
India's genetic burden is dominated by haemoglobinopathies ; the prevention model is carrier screening + prenatal diagnosis .
Periconceptional folic acid 400 µg/day is the single most cost-effective primary-prevention intervention.
Genetic counseling is non-directive and ideally pre-conception .
Prenatal diagnostic techniques are regulated by the PCPNDT Act (genetic diagnosis only, never sex determination).